Prostate cancer patients in Sussex are now part of a groundbreaking national trial, STAMPEDE2, which is revolutionising treatment approaches at the Royal Sussex County Hospital in Brighton. This trial is a testament to the commitment of University Hospitals Sussex NHS Foundation Trust to provide local patients with access to cutting-edge clinical research.

The trial is exploring the efficacy of combining standard hormone therapy with novel targeted treatments to improve outcomes for those with advanced prostate cancer. Patients are receiving either a pioneering radiopharmaceutical drug, which actively targets cancer cells, or a precision form of radiotherapy, both alongside hormone therapy.

One of the first to benefit from this trial is Darius Aibara, a 61-year-old from Worthing. Diagnosed with advanced prostate cancer, Darius is receiving the targeted radiopharmaceutical drug Lutetium PSMA. His experience has been positive, with no side effects, and he praises the excellent care provided by the Royal Sussex County Hospital team.

The trial, led by Professor Sabina Dizdarevic and her team, reflects a growing trend in cancer medicine towards using radiopharmaceuticals and precise radiotherapy to target tumours more effectively. Advanced imaging techniques, such as specialised PET-CT scans, are also being utilised to diagnose and map prostate cancer with greater accuracy, aiding in the planning of effective treatments.

Supported by the Sussex Cancer Fund, this trial not only advances clinical research in Sussex but also aims to deliver immediate benefits to cancer patients. As we continue to support innovative research and patient care, consider how Sawyer & Co can assist you with your property needs, ensuring you have the perfect home base during your health journey.